Cramer’s Week Ahead: Earnings from Eli Lilly, Alphabet, and Amazon. Plus, Jobs Data

As markets kick off the trading week, CNBC’s Jim Cramer is zeroing in on a powerhouse lineup of earnings reports from Eli Lilly (LLY), Alphabet (GOOGL), and Amazon (AMZN), alongside critical jobs data that could sway Federal Reserve rate cut expectations. With Eli Lilly’s Q4 results due Wednesday, February 4, investors are bracing for insights into obesity drug demand amid supply chain expansions, while Big Tech heavyweights Alphabet and Amazon face scrutiny on AI spending and consumer trends.[1][7][8]

Eli Lilly stands out as the week’s marquee pharma event, fresh off a 1.3% stock rally Friday to close at $1,037.15, pushing its market cap near $986 billion.[1] The surge followed the drugmaker’s bombshell announcement of a $3.5 billion investment in a new Pennsylvania manufacturing plant in Fogelsville, Lehigh Valley, dedicated to injectable weight-loss drugs like next-gen retatrutide.[1][4] This facility, backed by $100 million in state incentives, promises 850 permanent jobs and 2,000 construction roles, with construction starting in 2026 and operations by 2031.[1] CEO David Ricks emphasized meeting “increasing demand,” while manufacturing head Edgardo Hernandez highlighted boosted access to treatments.[1]

Why does this matter now? Lilly’s obesity portfolio—Mounjaro, Zepbound, and diabetes stalwart Trulicity—drives its leadership in the GLP-1 boom, but supply constraints have plagued the sector.[3] Rivals like Novo Nordisk’s Wegovy pill notched over 26,000 U.S. prescriptions in its second full week, per IQVIA data, signaling fierce oral competition that could pressure injectables.[1] Analysts remain bullish: Truist Financial’s Srikripa Devarakonda upheld a Buy rating January 26 with a $1,182 target (11% upside), while Bernstein’s Outperform call hit $1,300, praising oral opportunities, global diabetes growth, and 2026 upside surprises.[2] Zacks pegs Q4 EPS at $6.99, with the earnings call at 10 a.m. ET February 4.[5][6] Traders eye if Lilly can affirm supply ramps amid tariff risks and policy shifts on drug pricing.[1]

Shifting to tech, Alphabet reports Tuesday after the bell, under the microscope for Google Cloud’s AI infrastructure spend and YouTube ad resilience. Cramer often flags Alphabet’s ad dominance but warns of regulatory headwinds from antitrust probes. Expect focus on Gemini AI model progress and search market share versus emerging threats like ChatGPT. Consensus whispers robust revenue growth, but margins could pinch from capex.

Amazon follows Thursday, with e-commerce sales, AWS cloud dominance, and advertising as key watches. Post-holiday, investors crave proof of consumer spending steadiness amid inflation worries. AWS, powering much of AI hype, faces rival pressure from Microsoft Azure, but Cramer’s lens typically hails Bezos-era efficiency. Prime Day echoes and logistics investments could shine, though profitability hinges on cost controls.

Layering in macro, Friday’s nonfarm payrolls report looms large, potentially dictating rate cut odds. A soft jobs print (say, under 150,000 adds) might fuel March cut bets, boosting equities; blockbuster data could delay easing, hammering growth stocks like these earners.[1] Health care stocks, including Lilly peers like AbbVie and Pfizer, edged higher late last week, underscoring sector momentum.[5]

Cramer’s playbook? For Lilly, he’s long touted obesity drugs as transformative, but pre-earnings pops warrant caution—watch guidance on retatrutide trials, where late-stage data showed top-tier weight loss.[4] Capacity news tempers supply fears, yet delays from permits or labor loom.[1] Alphabet and Amazon? Buy dips on AI narratives, but pair with jobs clarity.

Risks abound: Political noise on drug tariffs could dent Lilly, while tech faces valuation stretches (LLY’s forward P/E towers post-rally).[1][2] Broader market? S&P futures hint green open Monday, but volatility reigns.

Bottom line: This week’s trifecta tests resilience. Lilly’s plant bet signals industrial-scale obesity play; Alphabet/Amazon gauge tech endurance. Jobs data ties it together—strong economy aids all, weakness spotlights Fed pivot. Tune into Cramer’s Mad Money for real-time calls, but position smart: Earnings beats could propel, misses crater. Markets reward preparation.

(Word count: 812)

Original source: CNBC Business – Cramer’s week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data